The 13 most recent market catalysts affecting $SNDX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Maintains Syndax Pharmaceuticals at Buy, Lowers Price Target
HC Wainwright & Co. reaffirmed its 'Buy' rating for Syndax Pharmaceuticals, indicating continued positive sentiment towards the company. However, the firm lowered its price target …
Nov 2, 2026
Corporate Catalyst
Bullish
Impact 85
Syndax Pharmaceuticals Reports Third Quarter 2026 Financial Results
Syndax Pharmaceuticals announced its third-quarter 2026 financial results, highlighting total revenue of $83.3 million, with significant contributions from Revuforj and Niktimvo. T…
Nov 2, 2026
Corporate Catalyst
Neutral
Impact 65
Syndax Pharmaceuticals Appoints Aaron A. Ondrey as Chief Financial Officer
Syndax Pharmaceuticals is appointing Aaron A. Ondrey as its new CFO, effective November 9, 2026, replacing Keith A. Goldan. This is a significant leadership change within the compa…
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 55
Syndax Pharmaceuticals' Revuforj Recognized as Best Product for Rare/Orphan Diseases by The Galien Foundation
Syndax Pharmaceuticals announced that its FDA-approved drug, Revuforj (revumenib), was named 'Best Product for Rare/Orphan Diseases of 2026' by The Galien Foundation. This award is…
Oct 13, 2026
Corporate Catalyst
Bearish
Impact 95
Syndax Pharmaceuticals shares are trading lower after the company announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint of the annualized rate of decline in forced vital capacity.
The failure of a Phase 2 clinical trial for a drug targeting a significant indication like idiopathic pulmonary fibrosis (IPF) is a major corporate catalyst for a biotechnology com…
Oct 13, 2026
Corporate Catalyst
Bearish
Impact 85
Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Syndax Pharmaceuticals experienced a significant pre-market decline after its MAXPIRe Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoin…
Oct 12, 2026
Corporate Catalyst
Bearish
Impact 95
Syndax Pharmaceuticals shares are trading lower after the company announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint of the annualized rate of decline in forced vital capacity.
The failure of the MAXPIRe Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis is a critical blow to Syndax Pharmaceuticals. Clinical trial results, especially for primar…
Oct 12, 2026
Corporate Catalyst
Bearish
Impact 85
Syndax Says Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis Missed Primary Endpoint, Halts IPF Development
This news is a major negative catalyst for Syndax Pharmaceuticals (SNDX). The failure of axatilimab in a Phase 2 trial for IPF, a significant and unmet medical need, eliminates a s…
Aug 21, 2026
Corporate Catalyst
Bearish
Impact 55
UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33
UBS analyst David Dai maintained a 'Buy' rating on Syndax Pharmaceuticals, signaling continued confidence in the company's fundamentals and future growth potential. However, the si…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 55
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40
JP Morgan analyst Anupam Rama maintained an 'Overweight' rating on Syndax Pharmaceuticals (SNDX) but lowered the price target from $44 to $40. This action suggests that while the a…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 75
Syndax Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results. Also, HC Wainwright & Co. lowered its price target on the stock from $40 to $38.
This headline represents a significant corporate catalyst for Syndax Pharmaceuticals. Mixed financial results often lead to investor uncertainty, and a lowered price target from an…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 92
Syndax Pharmaceuticals Q2 EPS $(0.55) Misses $(0.49) Estimate, Sales $72.788M Miss $79.323M Estimate
Syndax Pharmaceuticals reported Q2 losses of $(0.55) per share, missing the analyst consensus of $(0.49) by 12.24%. Concurrently, quarterly sales of $72.788 million fell short of t…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.